Cristina Martinez's spinal operation in Houston was expected to be routine. But after destabilizing her spine, the surgeon discovered the implant he was ready to put in her back was larger than he wanted to use — and the device company's sales rep didn't have a smaller size on hand, according to a report he filed about the operation.
Dr. Ra'Kerry Rahman went ahead with the operation, and Martinez awoke feeling pain and some numbness, she alleges. When Rahman removed the plastic device four days later and replaced it with a smaller one, Martinez suffered nerve damage and loss of feeling in her left leg, she claims.
Martinez is suing the surgeon, implant maker Life Spine Inc., and its distributor and sales representatives, alleging their negligence led to her injuries because the right part wasn't available during her first surgery. All deny wrongdoing. The case is set for trial in November.
The lawsuit takes aim at the bustling sales networks that orthopedic device manufacturers have built to market ever-growing lines of costly surgical hardware — from spinal implants to replacement knees and artificial hips commonly used in operations. Sales in 2019 topped $20 billion, though COVID-19 forced many hospitals to suspend elective surgeries for much of last year.
Device makers train sales reps to offer surgeons technical guidance in the operating room on the use of their products. They pay prominent surgeons to tout their implants at medical conferences — and athletes to offer celebrity endorsements. The industry says these practices help ensure that patients receive the highest-quality care.
But a KHN investigation found these practices also have been blamed for contributing to serious patient harm in thousands of medical malpractice, product liability and whistleblower lawsuits filed over the past decade.
Some patients allege they were injured after sales reps sold or delivered wrong-size or defective implants, while others accuse device makers of misleading doctors about the safety and durability of their products. Six multi-district federal cases have consolidated more than 28,000 suits by patients seeking compensation for injuries involving hip implants, including painful redo operations.
In other court actions, patients and whistleblowers repeatedly have accused device companies of failing to report injury-causing defects to federal regulators as required — or of doling out millions of dollars in illegal kickbacks to surgeons who agreed to use their products. Device makers have denied the allegations and many such cases are settled under confidential terms.
At least 250 companies sell surgical hardware, and many more distribute it to doctors and hospitals across the country. Spine companies alone obtained more than 1,200 patents for devices in 2018, according to an industry report. Many come to market through a streamlined Food and Drug Administration process that approves their use because they are essentially the same as what is already being sold.
"In orthopedics, we are inundated with a multitude of new implants that debut each year," Dr. James Kang, chairman of the orthopedic surgery department at Brigham and Women's Hospital, remarked at a Harvard Medical School roundtable discussion published in 2019.
Kang said surgeons often rely on industry "reps" in the operating room for guidance because it is "usually burdensome and difficult" for surgeons to know "all of the intricate details and nuances" of so many products.
Martinez's lawsuit says the process went awry during her May 2018 spinal fusion in Houston, an operation in which an implant is inserted into the spinal column to replace a worn or damaged disc.
Martinez was under anesthesia, with her spine destabilized, when Rahman discovered the Life Spine surgical kit did not contain any implants shorter than 50 millimeters, or about 2 inches. That was too large, according to the complaint. Martinez, a former day care worker, blames her injuries on the redo operation, which replaced the implant with a 40 mm version Life Spine supplied later.
Through his lawyer, Rahman declined to comment. In court filings, the surgeon has denied responsibility. His operating notes, according to court pleadings, say he had ordered "all lengths available" of the implant through a Life Spine distributor and its sales reps. In a June court filing, Rahman contends the "small area of leg numbness experienced by Ms. Martinez was a known complication of the first surgery … and was not the result of any alleged negligence."
In the court filing, Rahman also argues it was "appropriate" for him to rely on the sales reps and hospital staff to "inform him as to whether all materials and equipment needed for surgery were available."
Illinois-based Life Spine also denies blame. In court filings, it says the sales reps initially ordered a sterile kit that included only implants from 50 mm to 55 mm long, which it duly shipped to Houston.
At the time of Martinez's operation, Life Spine was the target of a sealed whistleblower lawsuit accusing it of paying improper consulting fees and other kickbacks to more than 60 surgeons who agreed to use its wares. Court records in the whistleblower case identify Rahman as one of the company's paid consultants, although he and the other surgeons were not named as defendants. Life Spine and two of its executives settled the matter in November 2019 by paying a total of nearly $6 million.
An orthopedic surgery expert hired by Martinez for her suit faulted Rahman for not making sure he had the right gear "prior to the start of surgery," according to his report. The expert also criticized the sales rep for failing to bring "all available lengths to the procedure or to inform Dr. Rahman that the necessary implants were not available," court records show. The sales rep and distributor denied any blame, arguing in court filings that they "met all applicable standards of care."
Frenzied Competition for Sales
Major device makers train a corps of sales agents, some recruited right out of college, to cultivate and work closely with surgeons — one likened the relationship to a caddy and an avid golfer. Duties can include lugging 20-pound sets of surgical hardware to the operating room, assuring it is sterile and knowing its specifications, though the reps are not required to have medical training or credentials.
Stryker, one of the nation's top four spine implant manufacturers, spends what it calls "a significant amount of time and money" to train reps. When hired, they typically "shadow" other reps for three to six months, then attend a 10-day intensive "Spine School" and other training. In all, the company said in a court filing, it typically takes eight to 18 months, often longer, to develop "long-term relationships" with customers.
For those who do, the jobs can pay handsomely. Veteran reps who influence which brands of hardware surgeons select command salaries and bonuses that can stretch into the low six figures and beyond, court records show.
The market is so hotly competitive that device makers typically require reps to sign contracts that prohibit them from working for a rival company in the same territory for a year or more — and aren't shy about suing to fend off raids on their staffs, court records show.
In 2019, DePuy Synthes sued an Alabama sales rep who jumped ship, blaming him for stealing away accounts "worth millions of dollars practically overnight." An arm of healthcare giant Johnson & Johnson, DePuy Synthes filed at least two dozen similar suits from 2014 through the end of 2020, court records show. Most, including the case of the Alabama sales rep, have been settled under confidential terms.
Some companies have spent lavishly to poach experienced sales agents — practices that can violate business conduct laws. One allegedly paid a New York sales pro a "staggering, seven-figure signing bonus." Another is said to have dangled an $800,000-a-year job as "director of surgeon education," while a gambit to make inroads in the Phoenix market dubbed "Sun Devil" guaranteed a branch manager a $500,000 annual salary, court records show. Another promised a sales agent $900,000 paid out over three years.
Whistleblowers and government investigators have argued for years that so much money changing hands can lead to kickbacks or other marketing schemes that corrupt medical judgment and endanger patients. Some injury suits also have blamed sales reps and distributors for staying mum about product deficiencies they observed in the operating room. These cases often are settled with no admission of wrongdoing.
Sometimes, surgeons help promote implants at medical meetings and other gatherings. Orthopedic surgeons and neurosurgeons received a total of about $511 million in industry consulting fees from 2013 through 2019 and nearly $300 million more for "serving as faculty or speaker" at industry-sponsored events, a KHN analysis of government data found. AdvaMed, the device industry's trade group, says doctors often take "primary responsibility" for training other doctors to use new devices. "Unlike a pill or injection, procedures to implant or equip medical devices for patients can be extremely technical and complex," said Scott Whitaker, the group's president and CEO.
Some prominent surgeons who touted products that later were recalled, or who helped train surgeons to use implants, have been criticized in pending injury lawsuits.
One is Dr. Brad Penenberg, an orthopedic surgeon in Beverly Hills, California, paid by Wright Medical Technology as a "key opinion leader," according to court filings. Multiple lawsuits cite a webinar for orthopedic surgeons that featured Penenberg and said hip surgery patients could resume "activities and lifestyles that include such things as tennis, horseback riding and snow skiing."
Injured patients are arguing in court filings that Penenberg and several other experts paid by the company knew of significant failures of the hip device. Penenberg did not respond to numerous requests for comment but in court papers denied the allegations.
Hundreds of patients are claiming injuries they blame at least partly on overly aggressive marketing by Wright Medical. In one 2020 lawsuit, a Montana man who had received a hip implant said he was taking a walk while in Arizona on vacation when he "felt a severe jolt in his groin and fell." He was out of cell range and could not get up or call for help. A "good Samaritan" called for an ambulance, which took him to a hospital in Gilbert, Arizona, where X-rays showed a fracture of the implant. It was removed and replaced. Wright Medical has denied the allegations.
Retired California psychologist Herb Glazeroff is suing Penenberg and Wright Medical Technology over a hip replacement that allegedly failed about five years after the surgeon installed it. In May 2019, Glazeroff was walking when he "suddenly dropped to his knees as his left leg gave out on him," according to the suit. He alleges that the hip had fractured, which required a painful second operation and "a long and arduous rehabilitation program" from which he has "yet to fully recover." Glazeroff argues that Penenberg failed to warn him about the implant's dangers even though the surgeon had been named in "multiple lawsuits" alleging device defects. Penenberg has denied the allegations.
Dozens of lawsuits have taken aim at Indiana device maker Biomet's advertising a hip replacement for "younger, more active patients" that showcased Olympic gold medal gymnast Mary Lou Retton. One ad says "Mary Lou lives pain-free, and so should you." Yet Retton suffered painful heavy-metal poisoning requiring the implant's removal and sued the company for damages, according to court records.
In a January 2020 court filing in Houston, Retton tried to block a subpoena seeking her deposition in a product liability lawsuit filed against Biomet by two patients in King County, Washington. The Washington case has since been settled and the deposition did not occur. But in a court filing opposing the subpoena, Retton confirmed she had a Biomet implant put in her left hip in 2005 and one on her right side about six years later. She said she promoted Biomet products from April 2006 through April 2013 and sued the company in January 2018, alleging the implants were defective. Retton said she and Biomet settled the suit in early 2019 "under confidential terms the parties find favorable to their respective positions. [Ms. Retton] values her long relationship with Biomet and her continued use of her [Biomet hip implants] and [Biomet] appreciates the support it has received over the years from [Ms. Retton]."
Defects Ignored, Downplayed
Whether touted by renowned surgeons or celebrities, orthopedic surgery marketing materials stress quick improvement in a person's quality of life. That proves true for most patients. Yet researching how often implants fail or cause life-changing injuries — and which brands have the best safety records — can be daunting.
The FDA requires device makers to advise the agency of information "that reasonably suggests" a device they sell "may have caused or contributed to a death or serious injury or has malfunctioned" in a way that could recur. The FDA posts the reports on a public website, with the caveat that they may convey "incomplete, inaccurate, untimely, unverified, or biased data."
KHN found that thousands of malpractice and product liability lawsuits have accused device marketers of concealing or downplaying hardware defects, leaving patients and their doctors in the dark about possible risks. In many cases, these claims are bolstered by company records, or actions by state or federal regulators. In 2019, for instance, DePuy Synthes paid $120 million to settle a lawsuit filed by 46 state attorneys general; the suit accused the company of advertising that a replacement hip it sold lasted three years in 99.2% of operations, when it knew of data showing that 7% had failed within that time. The company did not admit wrongdoing in settling the case.
British device company Smith & Nephew faces a federal civil proceeding comprising nearly 1,000 injury suits, including one that says the company "underreported and withheld" notices of malfunctions and "willfully ignored the existence of numerous complaints about [its] failures." An expert hired by the patients cites a company audit showing "significant adverse events" were logged from two days to 142 days late, while a corporate memo circulated among executives to push sales was titled "Milk the Cash Cow," according to court records. Smith & Nephew has denied the allegations and in one court paper called the expert's opinions "speculative."
A cluster of Florida injury cases pertaining to a knee implant from German manufacturer Aesculap alleges that the FDA cited the company for failing to report 25 adverse incidents — in some cases for a year or more — as a result of an inspection at its Hazelwood, Missouri, plant in September 2015. Aesculap has denied the allegations and the suits are pending in Florida's Indian River County Circuit Court.
John Saltis is suing spinal device company NuVasive over its handling of his complaint that a screw holding his spinal implant in place snapped in May 2016, about 17 months after his operation.
Saltis, 68, was two hours into his workday as a toolmaker at General Electric in Rutland, Vermont, when he felt sharp pain in his neck and shoulder, bad enough to send him to the hospital emergency room. A few days later, X-rays revealed the screw had broken and, according to Saltis, fractured vertebrae in the process.
Saltis said the San Diego-based device company told the FDA the incident caused no harm. But Saltis said he has lingering numbness and pain in his right hand. As a result, he said, his lifestyle has "changed dramatically." He sold his motorcycle and stopped biking and now relies on his left hand for simple tasks like opening doors and shaking hands — even plucking chips out of a bag.
"I miss things like bowling and playing toss with my grandkids," he said.
In 2019, Saltis sued NuVasive without a lawyer, hoping to show the $600 screw was defective. In a court filing, NuVasive said Saltis is arguing "the screw is defective because it broke." That's not good enough, according to NuVasive, which argues that Saltis must show the screw was "unreasonably dangerous" to press his claim. In late June, a federal judge agreed and dismissed the suit, though she allowed Saltis to amend his complaint, which he is pursuing. The case is pending.
"I was pain-free for a few months and would have stayed that way if the screw hadn't broken," Saltis said. "This can change somebody's life completely."
A Push for Change as Pandemic Eases
As hospitals resume elective operations stalled by the coronavirus, some industry critics see an opportunity to rethink orthopedic surgery practices — from sales to tracking of injuries.
Some want to keep industry reps out of operating rooms and place tighter restrictions on their access to hospitals. They say the current system needlessly drives up healthcare costs and exposes patients to risks such as infection from extra people in the operating room. Reps counter that their incomes have been dropping due to global purchasing arrangements that give hospitals greater say over prices for surgical equipment.
Sales reps say their technical knowledge and skills make operations safer for patients and note that many surgeons enjoy the security of having them present in the operating room. Reps also say they perform tasks that hospitals would need to hire additional personnel to do, such as keeping track of device inventories.
"The industry has embedded reps into the supply chain, and it is a hard culture to break," said Itai Nemovicher, president of the Orthopaedic Implant Co., which seeks to produce lower-cost implants.
Yet guidelines for "reentry" after COVID put out by AdvaMed and the American Hospital Association say medical device reps should deliver "services, information and support remotely whenever possible." The guidelines advise hospitals to use videoconferencing gear when it "does not compromise patient safety or privacy."
Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University, said device reps are viewed as part of the operating room team even though they are there "to sell products. That is pretty horrifying from a patient's point of view." She said hospitals should train staff to perform these functions. "Relying on sales reps in the OR is appalling. We need to come up with a better system."
Greater transparency might have helped Little Rock, Arkansas, resident Christopher Paul Bills. He sued Consensus Orthopedics, the maker of a hip implant system that he alleged failed and sent metal through his hip joint that his surgeon said in 2016 looked "as if a bomb had gone off." An Australian registry that tracks outcomes of operations had in September 2014 identified the implant as having a "higher number" of hip failures compared with other manufacturers, according to the suit.
Bills underwent four operations and spent more than a year in the hospital and in rehabilitation, costs borne by Medicare and private insurance.
"Mr. Bills was left with no right hip at all and his surgeon does not plan to install a replacement hip," the suit says. Bills uses an electric scooter to get around and hopes to graduate to hand-held crutches. "Since his right leg is useless, he will require a vehicle with hand-controls to drive," according to the suit. The company disputed Bills' claims and denied its hip system had any defects.
The case ended in 2019 when Bills died of cancer unrelated to his operations, said his lawyer, Joseph Saunders.
As the nation confronts its latest and worsening surge of covid cases, consumers are again facing delays getting tested, many turning to social media to complain.
This article was published on Friday, August 6, 2021 in Kaiser Health News.
Andrea Mosterman, an associate professor of history at the University of New Orleans, was already dismayed that she had to wait three days to secure a covid-19 test at a Walgreens near her home after being in contact with someone who had tested positive.
But on Sunday, when she showed up at the pharmacy drive-thru, she was told the store had run out of test kits and none was available anywhere in the city. “I told them I had a reservation, but they said it didn’t matter,” she said.
On Monday, eager to know her status and get back to work, she waited at an urgent care center for four hours to get tested. Within minutes, she was told she had tested negative.
While relieved, Mosterman said the process upset her. “It was incredibly irresponsible for them to promise me a test and have me wait three days to have the test and then to say, ‘We don’t have it.’ That was so frustrating,” she said.
As the nation confronts its latest and worsening surge of covid cases, consumers are again facing delays getting tested, many turning to social media to complain. The problem appears mostly in the South and Midwest, where infections driven by the virus’s delta variant are proliferating the fastest.
About 100,000 new cases of covid are being reported each day this week, up from about 12,000 a day in early July. Testing is up 41% in the past two weeks, to nearly 770,000 tests a day, according to The New York Times’ analysis of federal and state data.
Walgreens spokesperson Phil Caruso said the company has seen demand for tests “rise significantly, as testing volume across our stores doubled chainwide from June to July.” Overall, Walgreens has met the demand, he said, despite minor delays at some locations.
The shrinking supply of tests becomes clear when checking the websites of the nation’s two largest pharmacy chains, CVS and Walgreens — which have become popular test sites since cities and states curtailed testing to focus on vaccinations this spring.
On Wednesday, not a single appointment was available through Friday at 52 Walgreens locations in and around Jacksonville, Florida, which has one of the country’s highest infection rates. The earliest option was Thursday morning in Brunswick, Georgia, 70 miles away.
At CVS stores around Jacksonville, tests weren’t widely available until Tuesday, nearly one week later, when 21 of the closest 35 stores had appointments. If someone was willing to drive 15 to 20 miles, a handful of slots were available Monday, but nothing sooner.
Jacksonville’s Duval County had one public test site open this week, but health officials said they were weighing opening more because of increasing demand.
In Hillsborough County, home to Tampa, officials planned to open testing sites after reports from residents that they were waiting up to three days.
Experts say testing is vital for identifying patients to treat or isolate, as well as for tracking the disease’s spread.
“It’s understandable that resources have been pulled away, but testing is still a really important part of the pandemic,” said Gigi Gronvall, a senior scholar at the Johns Hopkins Bloomberg School of Public Health.
States closed many of their mass test sites over the past several months because of declining demand and the need to focus on vaccination.
Dr. Marcus Plescia, chief medical officer of the Association of State and Territorial Health Officials, said pharmacies likely have an adequate supply of tests, although they may have to redistribute them to keep up with increased demand in hard-hit areas.
“It’s no surprise there has been a little bit of a backup,” he said.
CVS Health spokesperson Tara Burke said her company is largely keeping up with demand, but she would not comment on consumer complaints about waiting three days or more to have a test.
“We continue to be able to meet the demand for COVID-19 testing, even with increasing numbers of patients seeking out tests at one of our more than 4,800 CVS Pharmacy locations across the country offering testing with same day and future day appointments in most geographies,” she said in an email response to KHN.
The nation’s largest pharmacies have been popular test sites, although consumers have other options, including going to their doctor, urgent care facilities or outpatient clinics. The tests at all these locations are available at no out-of-pocket expense.
Consumers can also test themselves at home with kits that cost as little as $25 and give results in 20 minutes.
But these tests aren’t as accurate as molecular tests analyzed in a lab. Rapid tests come with a higher risk of a false negative result, especially for people without symptoms; that is, the test shows you don’t have covid when you actually do.
A spokesperson for Abbott, which makes BinaxNOW, one of the home tests, said the company is working with retailers to meet “increased demand in certain areas of the country as case rates rise, and as testing needs and guidance changes.”
Even areas of the country that have not seen huge surges in covid cases have seen appointment slots fill up at the major pharmacies and other testing sites.
In San Diego County, California, on Wednesday, CVS appointments weren’t widely available until the weekend, and 13 of 20 Walgreens locations in the city of San Diego had no appointments before Friday.
San Diego County is running walk-up testing sites every day of the week, in addition to locations where appointments are required or recommended. In early July, the county — California’s second-most populous — recorded an average of 7,200 tests a day. By the end of the month, it averaged more than 11,800, with more than 15,000 tests on an especially busy day. To meet increasing demand, the county added four new testing locations this week and is working on a fifth, according to Sarah Sweeney, communications officer for the Health and Human Services Agency.
In Sacramento, the county-run sites accept only walk-ins, although some locations are hitting capacity and must refer people elsewhere, a county spokesperson said.
Going to one of the thousands of pharmacies advertising covid testing remains the first option for many people. Yet these days it can be frustrating.
Patricia Rowan said she struggled to find a pharmacy with an available appointment for her 67-year-old mother, Karen Liever. Liever had recently traveled to a conference and wanted to get tested near her home in Palm Bay, Florida, before visiting Rowan, who has young children who are not eligible to be vaccinated.
Rowan finally found a CVS about 25 miles from her mom’s home on Thursday.
In Florida, where covid hospitalizations are higher than ever, mass testing sites run by the state closed at the end of May and Gov. Ron DeSantis said local governments could use their CARES Act funding to restart testing operations if they want. DeSantis, a Republican, has spent this week trying to play down the surge in hospitalizations, saying most admissions are of younger adults and death rates are lower than a year ago. He also blamed the rise in cases on unvaccinated immigrants crossing the border illegally into Texas and the Southwest.
“People obviously have the opportunity to get a test,” DeSantis said Tuesday, the same day Orlando’s main public testing site closed early — for the 16th day in a row — because it had reached capacity. The governor noted that at-home rapid tests are available in pharmacies and criticized the effectiveness of past testing campaigns. “Quite frankly, we spent a lot of money on the testing. … I don’t think it did anything to bend the viral curve.”
As of Aug. 4, more than 480,000 people age 65 and older perished from covid — 79% of more than 606,000 deaths in the U.S. overall, according to the latest data from the Centers for Disease Control and Prevention.
This article was published on Friday, August 6, 2021 in Kaiser Health News.
As covid-19 resurges across the country, driven by the highly infectious delta variant, experts are extending our understanding of the pandemic’s toll on older adults — the age group hit hardest by the pandemic.
New research offers unexpected insights. Older adults living in their own homes and apartments had a significantly heightened risk of dying from covid last year — more than previously understood, it shows. Though deaths in nursing homes received enormous attention, far more older adults who perished from covid lived outside of institutions.
The research addresses essential questions: Which conditions appear to put seniors at the highest risk of dying from covid? How many seniors in the community and in long-term care institutions might have died without the pandemic? And how many “excess deaths” in the older population can be attributed to covid?
Of course, it’s already known that older adults suffered disproportionately. As of Aug. 4, more than 480,000 people age 65 and older perished from covid — 79% of more than 606,000 deaths in the U.S. overall, according to the latest data from the Centers for Disease Control and Prevention. (This is likely an undercount because it relies on death certificate data that may not be up-to-date or accurately reflect the true toll of the virus.)
Still, new information about older adults’ vulnerabilities is useful as covid cases climb again and unvaccinated people remain at risk. Some key results from studies published over the past few months:
Death rates varied among groups of seniors. In a study published in Health Affairs in June, experts from the Department of Health and Human Services analyzed data for more than 28 million people with traditional Medicare coverage from February 2020 (the approximate start of the pandemic) to September 2020. (Excluded were about 24 million people in Medicare Advantage plans because data crucial to the study wasn’t available.) The researchers compared data for this period with previous years, dating to 2015.
The study examines deaths among individuals with covid and reaffirms headlines that have trumpeted the toll among older Americans. Medicare members diagnosed with covid had a death rate of 17.5% — more than six times the death rate of 2.9% for Medicare members who evaded the virus.
A notable finding in the study: Medicare members with dementia were especially vulnerable. If diagnosed with covid, their death rate was 32%, compared with nearly 14% for those with dementia who weren’t infected. Also at substantially increased risk of death from covid were older adults with serious and chronic kidney disease, immune deficiencies, severe neurological conditions and multiple medical conditions.
Most of the seniors who died of covid lived outside of nursing homes. The HHS experts’ study reported 110,990 “excess deaths” due to covid during the eight-month period it examined — most likely an undercount because many older adults who died may not have been tested or treated for the virus. The term “excess deaths” refers to a death count higher than the number expected based on historical data. It is a core measure of the pandemic’s impact.
Of the excess deaths HHS experts documented, 40% occurred in nursing homes but a larger portion, nearly 60%, were seniors living in other settings.
Other studies suggest far more excess deaths. Estimates of excess deaths in the older population vary widely depending on the period studied, the data sources used and the type of analysis conducted. Another study, published in May in the BMJ (formerly known as the British Medical Journal), calculated 458,000 “excess deaths” in 2020 in the United States. About 72% were people 65 and older, according to the British and American authors.
About two-thirds of these deaths can probably be attributed directly to covid, the authors noted. Others might be due to acute medical care that was delayed during the pandemic, poor management of chronic medical conditions, the effects of isolation and other factors.
Assisted living residents were significantly affected. Data about the impact of the pandemic on assisted living residents has been scarce, in part because these facilities are regulated by states, not the federal government. A study out in June in JAMA Network Open found the death rate for assisted living residents in 2020 — as the pandemic unfolded — was 17% higher than in 2019. In the 10 states with the greatest community spread of covid, the death rate for assisted living residents rose by 24%.
“Efforts must be made to support assisted living communities as they work to address infection prevention and control to keep their residents safe,” said Kali Thomas, a study co-author and associate professor of health services, policy and practice at Brown University.
Underlying medical conditions played a major role. A study by researchers from the Cleveland Clinic and the Health Data Analytics Institute in Dedham, Massachusetts, is one of the first to suggest how many older adults who caught covid would have died from underlying medical conditions even if the pandemic had not been underway. It, too, examined 28 million people with traditional Medicare coverage from the approximate start of the pandemic (the end of February) through November 2020. (Of 28 million people in the study, more than 2.4 % had a confirmed covid diagnosis and 10% had a “probable covid” diagnosis.)
Other studies estimate excess deaths by looking at population-wide data. This study looked at individual data, using a highly complex methodology to calculate a preexisting risk of death for each person based on his or her age, sex, medical conditions and other demographic characteristics. Actual deaths in 2020 were then compared with expected deaths based on those preexisting risks. The report has been published as a preprint without peer review.
About 4% of Medicare members with confirmed or probable covid who were living in the community, in their own homes and apartments, would have died anyway from underlying medical issues, the authors estimated. With covid, the actual death rate climbed to 7.5%.
In nursing homes and other long-term care facilities, 20.3% of residents diagnosed with confirmed or probable covid would have died due to underlying medical issues; with covid, that rose to 24.6%, the authors calculated.
“This is a more accurate picture of the true toll of covid,” said Dr. Daniel Sessler, chair of the department of outcomes research at the Cleveland Clinic. “As it turns out, the greatest increase in deaths [from the virus], in terms of both raw numbers and an increased risk of dying, was in the community, not in long-term care residents.”
The bottom line. About 80% of people 65 and older have been fully vaccinated, leaving millions of seniors still at risk of covid. Special attention should be paid to older adults with dementia and other serious neurological conditions, kidney disease and multiple medical conditions. Older adults, especially the eldest groups, who are frail and who live alone or with little support in areas where the virus is spreading rapidly also deserve special outreach and attention.
We’re eager to hear from readers about questions you’d like answered, problems you’ve been having with your care and advice you need in dealing with the health care system. Visit khn.org/columnists to submit your requests or tips.
Pharmacy benefit managers, or PBMs, suspended in-person audits because of covid last year, shifting to virtual audits, much as in-person doctor visits shifted to telehealth.
The clock was about to strike midnight, and Scott Newman was desperately feeding pages into a scanner, trying to prevent thousands of dollars in prescription payments from turning into a pumpkin.
As the owner of Newman Family Pharmacy, an independent drugstore in Chesapeake, Virginia, he was responding to an audit ordered by a pharmacy benefit manager, an intermediary company that handles pharmacy payments for health insurance companies. The audit notice had come in January as he was scrambling to become certified to provide covid-19 vaccines, and it had slipped his mind. Then, a month later, a final notice reminded him he needed to get 120 pages of documents supporting some 30 prescription claims scanned and uploaded by the end of the day.
“I was sure I’d be missing pages,” he recalled. “So I was rescanning stuff for the damn file.”
Every page mattered. Pharmacy benefit managers, or PBMs, suspended in-person audits because of covid last year, shifting to virtual audits, much as in-person doctor visits shifted to telehealth. Amid added pandemic pressure, that means pharmacists such as Newman are bearing significantly more workload for the audits. It also has allowed benefit managers to review — and potentially deny — more pharmacy claims than ever before.
According to data from PAAS National, a pharmacy audit assistance service, while the number of pharmacy audits in 2020 declined nearly 14% from the year before, the overall number of prescriptions reviewed went up 40%. That meant pharmacies had to provide more documentation and stood to lose much more money if auditors could find any reason — even minor clerical errors — to deny payments.
The average audit in 2020 cost pharmacies $23,978, 35% more than the annual average over the previous five years, the PAAS data shows. And the number of prescriptions reviewed in September and October was fourfold over what PAAS members had seen in previous years.
Pharmacists have long complained that audits seem to have little to do with rooting out fraud, waste and abuse, but have become a way for these intermediary companies to enrich themselves. According to business analysts at IbisWorld, the pharmacy benefit manager market in the U.S. has grown to nearly $458 billion this year, up from less than $300 billion eight years ago.
Even before the pandemic, independent pharmacies were struggling financially with reimbursement rates they say are too low, the loss of customers to mail-order services or chain pharmacies, and a variety of measures by the benefit managers, including charging pharmacies fees and keeping manufacturer rebates for themselves.
Adding insult to injury: Many independent pharmacies report having received buyout offers from the large drugstore chains that own the PBMs, which pharmacists see as the primary reason for their financial struggles.
At a minimum, pharmacists say, virtual audits increase wait times and drive up costs for customers. At worst, the audits cost pharmacies thousands of dollars in payments for drugs already dispensed to customers, and may ultimately drive them out of business.
“It’s definitely pulling pharmacy staff away from their duties, and it’s become an administrative burden, which does have a direct impact on patient safety,” said Garth Reynolds, executive director of the Illinois Pharmacists Association. “They have to be the de facto audit team for the pharmacy benefit managers.”
Trent Thiede, president of PAAS National, said many of the more than 5,000 pharmacies he works with stepped up to offer covid testing and shots and to become an even bigger resource for customers during this health crisis. “With vaccinations in full swing, priorities should be focused on serving patients and our communities, not responding to audit requests,” Thiede said.
When auditors come in person, they primarily do the review themselves, occasionally asking pharmacists to pull additional documentation.
“In these virtual audits, you have to pull the prescription, put it through a copier of some kind, get everything aggregated, get all the signature logs. They want your license off the wall. They want all the employee licenses faxed,” Thiede said. “It’s a lot more laborious for these pharmacies.”
Express Scripts, one of the nation’s largest benefit managers, moved to virtual audits as a safety measure, said spokesperson Justine Sessions. “The virtual experience is very similar to the in-person audits in both scope and scale, and are conducted with the same frequency,” she wrote in an email. “When it is safe to do so, we intend to resume on-site audits.”
CVS Caremark, a benefit manager affiliated with the CVS pharmacy chain, and OptumRx did not respond to requests for an interview.
Dave Falk, who owns 15 Illinois pharmacies, said the largest audit he had ever seen before the pandemic was for 60 to 70 prescriptions, valued at $30,000 to $40,000. Then, last fall, his pharmacy in Robinson had to defend $200,000 in prescriptions in a virtual audit.
“None of these prescriptions were below $450,” he said. “These audits are not random. It’s a money grab by PBMs.”
He was appalled when the auditor asked his pharmacist to report the temperature of the refrigerator for perishable medications. The information has no bearing on whether prescriptions filled months earlier were appropriate.
“They’re looking for any reason to recoup funds,” Falk said.
After Falk and his pharmacist spent hours providing the documentation, the auditor initially denied $36,000 in drug payments, mostly because of missing patient signatures. Like most pharmacies during the pandemic, Falk’s had stopped collecting patient signatures last year for safety reasons. Major trade associations representing the PBM companies and pharmacies had come to an agreement last year that patients wouldn’t need to sign for medications provided through mail order, delivery or curbside pickup.
Nonetheless, Falk’s staff had to track down dozens of patients to have them sign affidavits that they had received the prescriptions, reducing the auditor’s denial to $12,000.
“That’s $12,000 for ridiculous reasons,” Falk said.
In Newman’s eight years as a pharmacist, he said, he has undergone six audits, all but the most recent done in person. In the virtual one, conducted on behalf of the health insurer Humana, Newman uploaded his documentation before the deadline. But he, too, was flagged for missing signatures.
Dan Strause, president and CEO of Hometown Pharmacy in Madison, Wisconsin, said his pharmacies received more than 1,000 pages of audit requests last year, covering more than $3 million in prescription claims. That represented 1.5% of his company’s total annual revenue. He said pharmacists saw a surge last year of what they call predatory audits, which look for ways to deny legitimate payments for prescriptions.
“What they did in 2020 was reprehensible,” Strause said. “While we were taking care of patients, they’re sitting back in their comfy offices figuring out ‘How can we make money off this? Can we find a loophole? Can we find a missing document? Can we find a reason to take back stuff?’”
Lisa Dimond, a spokesperson for Humana, said the company is required by the government to perform audits to see if pharmacies are adhering to regulations, but conducted fewer audits and reviewed fewer prescriptions in 2020 than in 2019.
“We have worked to reduce as much administrative burden as possible on our network pharmacies, offering extensions, when needed, while still working to ensure pharmacies are filling prescriptions appropriately for the safety of our members,” she said in a statement.
Pharmacists bristle when large pharmacy chains that operate their own benefit managers offer to buy their stores, acknowledging that times are tough. Joe Craft owns the Happy Druggist chain of pharmacies in central Ohio. He said he regularly receives letters seeking to buy his business from the same companies that cause him to lose an average of $6,000 in payments with every audit, about a week’s worth of revenue for a single drugstore.
“When you read that letter, you’re thinking to yourself, ‘Hell, yeah, times are tough,’” he said. “Of all people, they should know.”
And oftentimes, when independents are sold to bigger chains, those drugstores are shut down, and the chain pharmacy directs customers to one of its locations miles away.
Thiede and many pharmacists believe that, while in-person audits may resume after the pandemic, virtual audits may be here to stay as well.
“They can do more because they don’t have to travel and fly across the country and sit in your pharmacy all day long,” Thiede said. “They can just do it from their home and accomplish more.”
Detroit’s iconic Herman Kiefer complex for decades was synonymous with public health in the eyes of many city residents. By the time the complex was abandoned in 2013, it had fallen into vermin-infested disrepair and housed a fraction of the dedicated employees who once walked its halls.
This article was published on Friday, August 6, 2021 in Kaiser Health News.
If you were growing up in Detroit in the 1970s or ’80s, chances are you knew the city’s Herman Kiefer public health complex by both sight and reputation.
Opened at the turn of the century and later enhanced by renowned industrial architect Albert Kahn, the imposing brick complex was named after a local infectious disease doctor. As the city grew, so did the complex and the services offered within, becoming synonymous with public health in the eyes of many families and residents.
For decades, it was where you went to pick up birth records, get tested for tuberculosis, get vaccines or undergo discreet diagnosis and services for sexually transmitted diseases. It was even a place some parents told their children to go to if they needed help — the way other parents tell their kids to go to the police if they’re in trouble.
That was before the lean years that led into the Great Recession of 2008. By the time the complex was abandoned more or less overnight in 2013, it had fallen into vermin-infested disrepair and held a fraction of the dedicated employees who had once walked its halls. City officials gave up on the building — and dismantled the public health department it had come to represent. Eventually, the city sold Herman Kiefer to an out-of-town developer, who has marketed it as a commercial complex.
Across the nation, public health departments have seen dramatic cuts over the past decade. It is a nationwide phenomenon, hitting communities big and small, rich and poor. When state and local government revenues falter, health departments are often the first to lose funding.
When politicians shutter a school or close a subway stop, the impacts are immediate and visible, sparking sharp public blowback. But when a health department fires its contact tracers or closes its infectious diseases lab or stops testing children for lead exposure, the impact is more subtle.
At least at first.
Detroit often experiences a magnified version of the nation’s economic and health woes, and the same holds true of its experiment to streamline and privatize public health services. A health department that had 700 employees in 2008 had just five by the end of 2012. Though it has slowly been rebuilding since 2014 — it now employs approximately 270 people — damage done during the leanest years has been on stark display amid the ravages of the covid-19 pandemic.
***
Vernice Davis Anthony loves thinking back on the good years. In the 1970s, she was one of dozens of public health nurses working for the Detroit Health Department. Originally from Pennsylvania, Davis Anthony moved to Detroit to attend nursing school at Wayne State University, where, as a young Black woman, she’d heard she could get a fair shot at an education and career in the majority-Black city.
She and her co-workers walked the neighborhoods building connections and trust, visited the home of every new mom, and worked in schools, tracking cases of infectious diseases and making sure kids got immunized. Wearing health department badges and uniforms, she particularly liked doing home visits in vibrant Southwest Detroit, then home to Puerto Ricans, Mexicans, Middle Easterners, Appalachian whites and Southern Blacks. The power dynamic captivated her: Unlike a hospital, where doctors and administrators ran the show, the families ultimately decided whether she could come in. “When you are in their home, the balance of power has shifted,” she said.
In those days, she said, the health department had resources to back up its mission, including a world-class laboratory and a pharmacy that provided discounted medicines to residents. It ran clinics throughout the city’s sprawling neighborhoods.
It also had political clout. When AIDS emerged as a devastating public health threat in the early 1980s, at the same time intravenous drug use had become rampant in some neighborhoods, the health department funded community groups to educate residents on the dangers of the human immunodeficiency virus and sharing needles.
George Gaines, then the city’s deputy health director, recalled a conversation in the 1980s when he pleaded with Mayor Coleman Young to let him hand out clean needles to drug users, a controversial topic even today. “Give them the needles,” he said Young told him. “Just keep your name out of the paper.”
For years, Gaines dedicated resources to drug treatment programs aimed at helping poor inner-city families, even as federal funding for drug addiction was slashed.
While there’s no way to prove those early efforts prevented an explosion of HIV, said Eve Mokotoff, who handled HIV data for Michigan from 1986 through 2012, that work was clearly vital in turning attention to the threat HIV posed in low-income Black communities even as much of the nation’s medical community focused primarily on the threat to gay white men.
The people leading the health department at the time had “a fierce love for that city, and fierce in the most positive sense of the word,” Mokotoff said. “When they saw this was going to happen, they weren’t going to close their eyes to it. They weren’t sitting ducks. They wanted to prevent it.”
Those were the gratifying years when Detroit health officials were often called in by other cities to teach strategies for lowering rates of child lead poisoning, HIV infections and Black infant mortality.
Gaines can hardly fathom how it all fell apart so fast.
***
In the final decades of the 20th century, white flight to the suburbs, the struggles of the auto industry and offshoring of manufacturing all hit Detroit hard. Then came the predatory lending that helped trigger the Great Recession.
From 2008 to 2010, with the city’s tax base shrinking, the health department shed more than 70% of its employees. By 2012, Mayor Dave Bing, a professional basketball player turned businessman, was preparing the city for bankruptcy. Told they had to cut costs further, leaders of the stripped-to-the-bone health department made a radical proposal: privatize and outsource services by handing nearly all their work to a nonprofit to be assembled from scratch and dubbed the Institute for Population Health.
Health departments around the country have survived perennial funding declines by turning to grants and private entities to carry out some of their work. What was unprecedented about Detroit was that it wasn’t just a few programs to be outsourced; it was essentially all of the city’s health services.
Those involved say it was a necessary step to save the department from the volatility of the municipal bankruptcy and the weight of union and pension obligations. In theory, it would allow the city to maintain its core health mission, even as it went through a financial overhaul.
But critics say the arrangement had nothing to do with the well-being of residents. “It was not a decision made to improve the health of people. It was purely an economic decision,” said Phyllis Meadows, director of the city health department from 2004 to 2009. “This was political health; it wasn’t public health.”
Though a messy battle over the plan ensued — by Michigan law, the city was obligated to provide certain public health services — Bing won. By October 2012, health services were no longer housed at Herman Kiefer and nearly all the department’s duties had been outsourced to the new nonprofit. The following year, the governor installed an “emergency manager” whose powers superseded those of elected officials.
Davis Anthony, who had moved on to other health agencies, initially supported the reorganization and returned to run the stripped-down, five-person city department that remained from 2012 to 2014. But her experience ultimately led her to believe public health at its very core must be a government function. The skeletal city staff was too small to provide proper oversight of public funds. “When you have public health funding that’s going directly from the state to a nonprofit without any accountability, that was a problem,” she said.
Community organizers and former employees say the nonprofit may have been well-meaning, but public health all but disappeared from many Detroiters’ lives. Residents had no say in funding priorities. And there was no government agency with expertise and political support to serve as a backstop for the health of residents.
A local health department is charged with prevention, protection and health promotion, said Robert Pestronk, former health officer for Genesee County, Michigan, home to Flint, and former executive director of the National Association of County and City Health Officials. “It’s not about conducting business. It’s to make sure there’s a place in our society where the roots are nourished by those concepts.” Underfunding undermines that role, he said. “We live in a culture where, if you have resources, you gain some respect.”
After the privatization, health officials lost the political influence needed to protect residents from basic threats, said former employees and city residents. That includes remaining largely silent as Detroit’s Water and Sewerage Department, struggling with its own bankruptcy filing, began shutting off water to the homes of people late paying their bills. From 2014 to 2020, an estimated 141,000 customers lost water at some point. The shutoffs were crushing for low-income residents, many of them Black families, living in neighborhoods already buckling under the weight of the city’s economic collapse.
“How are they going to use the restrooms? How are they going to cook? How are they going to prepare formula for babies?” said Dr. Kanzoni Asabigi, who held top public health positions with the city before abruptly retiring in May 2020 over disappointment at city officials’ response to the pandemic. “Everybody needs water to live.”
Gaines was so disgusted by the water shutoffs that at 90 years old he conducted research on the health effects in hopes elected officials would end the policy. Instead, it took a global pandemic. As officials nationwide advised Americans to wash their hands to fight the new coronavirus, Michigan Gov. Gretchen Whitmer issued a temporary moratorium on water shutoffs. In mid-December, Detroit Mayor Mike Duggan announced a plan to extend the moratorium through 2022.
***
It was Duggan who initiated the return of public health services to government control when he took office in 2014, less than two years after the department was all but shuttered. But rebuilding has been a painful process.
Duggan hired as executive health director Abdul El-Sayed, a native of the Detroit suburbs who was then a professor of public health at Columbia University. His first order of business was to move the department out of a conference room in the back of the city parking department. He then was tasked with revamping animal control, yet another of the department’s duties, to combat negative headlines generated by the shelter’s high kill rate.
From there, his job became contentious, as he got into public feuds with his boss over a range of health issues: refineries that were spewing toxic fumes in a city overburdened by asthma, sweeping neighborhood demolitions that communities believed were causing increases in child lead poisoning, and the water shutoffs to tens of thousands of Detroiters. He said he didn’t play the politics well but felt compelled to weigh in.
“There’s not that much money in making sure that babies have what they need to thrive. There’s not that much money in making sure that restaurants are up to code,” said El-Sayed. “If there was, private industry would hop to do it.”
After less than two years with the department, he resigned to wage an unsuccessful run for governor.
El-Sayed was succeeded in 2017 by Dr. Joneigh Khaldun. She had joined the department as medical director the previous year, coming home to Michigan after serving as chief medical officer in the Baltimore City Health Department, which has 900 employees for a population 10% smaller than Detroit’s. When Detroit was hit by an outbreak of hepatitis A in 2016 during her first week on the job, she recalled, the city had no public health lab; she didn’t know where to find its contact tracers, who were state employees, and there was no protocol for a vaccination campaign.
“That infrastructure of, how do you quickly respond to an outbreak? How do you stand up clinics? How do you get the communications out so that people know where to go? That was not there,” Khaldun said.
Khaldun left in 2019 to become the chief medical executive for Michigan’s Department of Health and Human Services. When covid arrived in March 2020, the fledgling system she had set up with colleagues was Detroit’s first line of defense. Amid the feeble response, the coronavirus cut a broad and deadly swath through the city, quickly overwhelming area hospitals and hitting hard in tightknit communities of health care workers, churchgoers and ballroom dancers.
In the year since, 1 in 10 Detroiters have been infected with covid and more than 2,400 have died — more than twice the number in Baltimore. Detroit’s covid death rate is roughly double the national rate.
The pandemic has raised the department’s profile, but officials are struggling to win back the community’s trust. When the Centers for Disease Control and Prevention updated its mask guidance in May, saying indoor masking was no longer necessary among fully vaccinated people, just 20% of Detroit residents met that definition. Nearly three months later, just 34% of the city’s residents are vaccinated, compared with 54% of Michigan residents and 50% of U.S. residents overall.
And with all hands on deck to fight covid, neglected public health issues have plunged into deeper obscurity. Programs to prevent and treat childhood lead poisoning were put on hold. The childhood vaccination rates against diseases like measles and mumps have dipped below 50%.
On nearly every health measure — HIV rates, health insurance coverage, drug-related deaths, smoking, STDs, vaccination rates, asthma and obesity — Detroiters are faring worse than Michiganders as a whole. While the average life expectancy in Michigan is 78, it is 72 in Detroit, with some neighborhoods falling as low as 62. Maternal mortality is nearly triple the state average, as is infant mortality. A 2018 health needs assessment found that 9% of children under age 6 have blood lead levels elevated above accepted thresholds, a figure that jumps to 22% in some neighborhoods.
For all the federal relief money that came pouring in for covid, the health department still lacks the resources for even the most basic services. In May, the Detroit City Council approved an $87,000 contract to outsource testing related to sexual and reproductive health. Residents who are tested at a city clinic for HIV, STDs or pregnancy-related concerns will have their labs sent to San Antonio for processing.
Today, Detroit’s health department has an operating budget of $41.7 million, money that mostly comes from state and federal funds or grants.
“The pandemic really put the issue of health care disparities in everybody’s face,” said Davis Anthony, and that gives her hope that the city and state will continue to reinfuse the department with resources. But even if that happens, restoring its place in city life after years of absence isn’t a given. “It’s going to be a difficult road to travel,” she said.
A plan by Providence and Kaiser Permanente to build a new medical center in the High Desert region of California is the latest example of leading hospital chains seeking market advantage.
They intend to spend up to $1 billion to build a hospital in Victorville, a city of about 123,000 that sits 85 miles northeast of Los Angeles. The site is only 11 miles from a hospital Providence already owns, and plans to close, in the adjoining city of Apple Valley. The new site is next to Interstate 15, a major artery that cuts across a swath of the Mojave Desert and through the San Bernardino Mountains toward the more populous cities of Fontana, Riverside and San Bernardino. That location should help ratchet up market share in an area whose population has skyrocketed over the past four decades. Victorville's population has nearly doubled since 2000.
The unusual pairing of very different healthcare giants — a Catholic chain and an HMO-only model — will result in a facility available to both systems' patients. But Kaiser Permanente members won't be able to get certain reproductive services, including abortion, at the hospital because of Providence's Roman Catholic affiliation.
According to a filing with the state, the new hospital will be fully functional by 2028. KP will contribute 30% of the capital to build it, and Providence 70%. Providence and KP hope to win state approval for their plan and sign a definitive agreement by year's end.
The new facility will help the partners take on their two main Victorville competitors — Desert Valley Hospital, owned by Prime Healthcare Services, and Victor Valley Global Medical Center, owned by KPC Health. Prime is a large national healthcare system, though not as large as Providence, which is the nation's 10th-largest. Kaiser Permanente, which is both an insurer and a provider, has 39 hospitals and 724 medical offices across eight states and Washington, D.C. (KHN is not affiliated with Kaiser Permanente.)
A key part of the plan is for Renton, Washington-based Providence to close its 65-year-old St. Mary Medical Center in Apple Valley. It says costly upgrades required under looming state earthquake mandates don't make economic sense.
"Retrofitting the current hospital would cost close to the same amount as building the new hospital, but you'd have to do it while operating the hospital," said Erik Wexler, president of Providence South, which includes the group's operations in California, Texas and New Mexico.
The seismic mandates require that by 2030 all hospital buildings used for patient care be capable of functioning in the aftermath of a major earthquake. The California Hospital Association, the industry's main lobbying group, and seven other hospital advocacy groups are trying to persuade state lawmakers to soften the law. They warn it would cost California hospitals over $100 billion and force many to close.
The costs of meeting seismic safety codes have also factored into the business decisions of other California hospitals.
In December 2017, Pacific Alliance Medical Center in Los Angeles closed, citing the financial burden of seismic retrofitting. Sutter Health has said it will shut its Alta Bates hospital in Berkeley by 2030 because meeting the state seismic standards would not be cost-effective.
But the Providence-KP deal is as much about competition as it is about earthquake readiness. Even if hospital lobbyists persuade state lawmakers to soften the requirements, there's no turning back on the project, Wexler said.
Though Providence has 51 hospitals in seven states, associating with KP can burnish its credentials. KP, for its part, would get a local hospital where its approximately 110,000 members in the region can go for more than just emergency care.
That makes the deal advantageous for KP members. At present, they can use St. Mary, Desert Valley or Victor Valley Global for emergency services. But for any nonemergency hospital care, they must travel to the nearest KP hospital, 40 miles away in Fontana.
If the proposal goes through, they will have a hospital for almost all their needs much closer to home, said Bill Caswell, a senior vice president at Kaiser Permanente.
That means reduced spending on emergency care for KP members at other hospitals in Victorville — including the one owned by Prime Healthcare, with which KP has a history of mutual hostility.
And having a local hospital could help KP increase its membership in the High Desert, said Kevin Holloran, who oversees financial analysis of nonprofit hospitals at Fitch Ratings, which provides credit ratings and research for investors.
Some employers and individuals prefer KP but are put off by its lack of a nearby hospital, so they sign up with other large insurance companies such as Blue Shield of California, Anthem Blue Cross, Cigna or Aetna, Holloran said. Having a Kaiser Permanente-affiliated hospital in their community might persuade them to switch, which could ultimately draw business away from Prime, KPC and even Providence-affiliated physicians, he said.
Kaiser Permanente has affiliations with 12 other hospitals across California allowing its members full access.
KP doctors will be full-fledged members of the medical staff at the new hospital, but it will be operated by Providence, which follows Catholic healthcare directives that prohibit abortions, insertion of birth control devices and certain other forms of reproductive care. The KP doctors will be bound by those directives while working in the hospital.
Providence is currently embroiled in a legal battle with Orange County's Hoag Hospital, one of its affiliates, in part over allegations by Hoag that Providence illegally restricts reproductive care for Hoag patients.
Unlike Hoag, KP can accommodate its members' reproductive healthcare needs at its existing facilities, including medical offices in Victorville and nearby Hesperia and its Fontana hospital, Caswell said.
The Providence-KP plan is unsettling to many residents of Apple Valley, a town a little more than half the size of Victorville. St. Mary is the town's biggest employer and has been around since 1956. The new hospital would be Victorville's third, while Apple Valley would be left with none.
"My main concern is that the people in Apple Valley would have to go quite a bit farther for a hospital," said Yvonne Spallino, an 85-year-old Apple Valley resident. "Why don't they build one over here? Why is it over there?"
Scott Nassif, a member of the Apple Valley Town Council who sits on the board of the St. Mary Medical Center Foundation, said many people in Apple Valley felt blindsided by the news their hospital would close.
"We worked so hard to have that hospital. The original developers of Apple Valley donated the land for it. Residents have financially supported it, and all of a sudden, 'Poof — thank you, but we're moving,'" said Nassif. "Everybody is still a little bit in shock."
The loss of nearby emergency care would hurt Apple Valley residents the most, Nassif said. Eleven miles doesn't sound like much, but it can take more than a half-hour to get to the site of the new hospital if traffic is heavy, he said.
Nassif, who lives close to St. Mary, is keenly aware of that time factor. One night in 2016, he began having severe chest pains and was rushed to the emergency room. "Basically, when I got there, I was on my way out," he said. "If I'd had to go anywhere else, I probably wouldn't be around."
There has been talk of converting St. Mary to an emergency care-only facility. At present, state law does not allow standalone emergency rooms, but there is a move afoot to modify that law.
If such a law were to pass, Wexler said, Providence would consider an ER at the Apple Valley site, but he added, "We can't commit to doing it."
Federal health officials will likely reject Montana's request to include work requirements for beneficiaries of its Medicaid expansion program, which insures 100,000 low-income Montana adults, state officials said.
Three years after the Trump administration encouraged states to require proof that adult enrollees are working a certain number of hours or looking for work as a condition of receiving Medicaid expansion benefits, the Centers for Medicare & Medicaid Services has reversed course under Democratic President Joe Biden.
"CMS has communicated to [the Montana Department of Public Health and Human Services] that a five-year extension of the Medicaid expansion waiver will not include work/community engagement requirements," health officials wrote in a Medicaid waiver amendment application out for public review.
It's unclear what that means for the future of the Montana program. In 2019, Montana lawmakers approved extending the 2015 program — the Supreme Court made the Medicaid expansion provision in the Affordable Care Act optional for states — as long as it included work requirements. Those requirements were a key condition for the moderate Republicans who joined Democratic lawmakers to muster enough votes to pass the 2019 bill over the objections of conservative GOP legislators.
The state's position officially remains that it wants "to condition Medicaid coverage on compliance with work/community engagement requirements," according to the amendment application. If state negotiators are proposing an alternative, they have not disclosed it.
If CMS does not approve the waiver with the work or community engagement requirements, the state health department will operate Medicaid expansion according to what is approved and await legislative review of the program, said department spokesperson Jon Ebelt.
The Montana Medicaid expansion program is scheduled to end in 2025 if the legislature doesn't renew it. State lawmakers meet every other year, giving them the 2023 and 2025 sessions to consider changes to the popular program, which enrolls 10% of the state's population.
Meanwhile, Republican-led lawmakers and Republican Gov. Greg Gianforte's administration have proposed other measures designed to trim the Medicaid expansion rolls and defray costs, including raising the premiums some enrollees pay and ending a provision that allows 12 months of continuous eligibility regardless of changes in income. Those proposals are also pending federal approval, and it was in the state's application for the 12-month continuous eligibility waiver that the status of the work requirement negotiations was disclosed.
In June, the number of Montanans enrolled in the expansion program passed 100,000 for the first time in its 5½-year history. The program provides health insurance coverage to adults who earn up to 138% of the federal poverty level, which is $26,500 for a family of four.
The negotiations between state and federal health officials involve what's called a Section 1115 waiver amendment application to CMS, which is made when a state Medicaid program seeks to deviate from federal requirements. CMS' deadline for acting on the application, originally submitted in 2019, was extended to Dec. 31, 2021, because of the COVID-19 pandemic.
The Trump administration approved work requirement waivers in 12 other states, though no states are implementing those requirements, either because of the pandemic or lawsuits, according to research by KFF. (KHN is an editorially independent program of KFF.)
Asked to comment about the Montana negotiations, CMS officials said Medicaid is a lifeline for millions of Americans who would be put at risk by work requirements.
"The pandemic and uncertainty surrounding its long-term social, health, and economic effects exacerbate the risks associated with tying Medicaid eligibility to requirements that have been demonstrated to result in significant coverage losses and substantial harm to beneficiaries," an unattributed CMS statement said.
Montana health department officials said in their waiver application that they expect negotiations with CMS to be finalized in the fall and the Medicaid waiver to be extended for five years starting in January. That Jan. 1, 2027, end date of the waiver, presumably without work requirements, would be subject to the state's own 2025 sunset.
The 2019 state law granting a six-year extension to the Medicaid expansion included the condition that work and community engagement be part of it. The law states beneficiaries must work at least 80 hours each month or be engaged in a job search or volunteer work, unless they are exempt for specific reasons, such as pregnancy, disability or mental illness.
State Rep. Ed Buttrey (R-Great Falls), who sponsored both the 2019 bill and the 2015 bill that created the original Montana Medicaid expansion program, said lawmakers added the 2025 sunset so that they could assess and revise the program, if needed.
"So in a couple sessions we'll have to take another look at the program and the federal rules and find out how things are performing and how we want to move forward." Buttrey said.
He defended work requirements, saying the goal of Medicaid expansion has always been to create a healthy workforce to improve Montana's economy.
State Rep. Mary Caferro (D-Helena) said work requirements can cause unnecessary hurdles for people who qualify for the Medicaid expansion program. She said that 7 in 10 Montanans who gained Medicaid coverage under the expansion are already working and that the rest can't for various reasons, such as they are caregivers, have an illness or are going to school.
"Work requirements don't make sense for our particular population," Caferro said.
The disclosure of the ongoing work requirement negotiations was made in an application that seeks to eliminate 12-month continuous eligibility for Medicaid expansion beneficiaries plus a separate group of Medicaid beneficiaries with severe disabling mental illnesses.
Currently, those people are enrolled in the Medicaid expansion program for a full year regardless of changes in income or assets. The proposed change, included in the state budget passed by lawmakers earlier this year, would kick enrollees out of the program if their income rises — even if only temporarily because of a one-time payment or seasonal work.
The state also proposes increasing premium payments for certain expansion beneficiaries to up to 4% of their household income in the same waiver application that proposes work requirements.
Buttrey said the goal was to offset the costs of Medicaid so that the people benefiting from it bore some of the costs, and hopes CMS will approve the proposal.
The public comment period for the state's waiver applications is open until Aug. 31. A legislative committee is scheduled to meet Tuesday to review the proposals.
The massive spending bill is the first of two likely to at least delay the so-called Medicare rebate rule released at the end of the Trump administration, which has yet to take effect.
This article was published on Thursday, August 5, 2021 in Kaiser Health News.
The Senate's release of its bipartisan infrastructure plan signals that lawmakers are poised to throw former President Donald Trump's belated bid to lower Medicare drug prices under the bus — not to mention trains, bridges, tunnels and broadband connections.
That's because the massive spending bill is the first of two likely to at least delay the so-called Medicare rebate rule released at the end of the Trump administration, which has yet to take effect. Congress would use the projected costs of that rule to pay for more than half a trillion dollars in new infrastructure.
What has infrastructure spending got to do with Medicare drug rebates?
Bear with us as we explain the mad logic of how Congress intends to pay for a spending program with money that doesn't really exist. Tossing Trump's reform under the steamroller to offset other costs offers a window into the convoluted process of congressional budgeting: Senators say the plan will provide billions of dollars of savings, even though the federal government has never spent a dime on the rebate rule. And it focuses attention on the intractable problem of bringing down drug prices: The rule would take money from drug industry brokers and provide refunds to consumers, which would suggest it was saving them and Medicare money. Yet budget analysts said the process would cost the government billions of dollars.
Let's start with the Medicare drug rebates.
The way things work now, pharmacy benefit managers, which are often owned by insurance companies, negotiate with drugmakers to get significant reductions on a drug's list price. They pass the bulk of that savings along to Medicare and the insurers, who can pocket some of it and use it to lower overall premiums for customers who buy drug plans in Medicare Part D.
While customers benefit from a lower premium, it doesn't mean they actually get a better price for their drugs, said Gerard Anderson, a professor of health policy at Johns Hopkins Bloomberg School of Public Health.
That's because a patient's price is not based on the rebate but on a share of the original list price of the drug. If a drug costs $100, and a patient's share is 25%, they pay $25, regardless of how big a rebate the PBM got for the insurer.
It thus serves the interest of the PBM for the drugmaker to raise prices. "When the list price goes up, your patient responsibility goes up, so the patient ends up paying more," Anderson said. "The PBM makes money because, when the list price goes up, the rebate is larger. But the patient loses, because their cost sharing is based often on the list price."
Since the PBM controls the formulary that says which drugs are covered in a given plan, Anderson and others point out, it is also in the interest of a drug company to raise list prices if it wants the PBM to give its drugs preferential treatment.
"If you've got two drugs that are available to take care of some heart disease, the PBM wants the drug that's going to pay them the most money, and the money is the difference between the list price and the actual transaction price," Anderson said. "So the higher the list price, the higher the profit margin for the PBM. So the drug company who wants their drug on the formulary has to raise their price in order to give the PBM a greater profit."
A wrinkle in federal law allows that to happen. Typically in federal contracting, if someone sets a high price to give the buyer a cut, it's considered a bribe or a kickback, and it's illegal. But the law that created the Part D drug program carved out what's known as a safe harbor to allow such deals in the hope that negotiations would lower overall costs.
The Trump administration's rule attempts to end the perverse incentive by taking the safe harbor away from the PBMs and giving the rebate to customers at the pharmacy counter. Then-Health and Human Services Secretary Alex Azar said costs would fall by about 30%.
But the effort had two major problems. First, the rule was challenged in court by the PBMs on procedural grounds. Second, the Congressional Budget Office predicted that, rather than save money, it would end up costing the federal government $177 billion over 10 years because drugmakers would be less likely to provide as many discounts, causing a spike in Medicare drug coverage premiums.
The Biden administration delayed the rule, and could scrap it, making that $177 billion cost more theoretical than real. But that's where congressional budgeting comes in.
A chief selling point of the infrastructure proposal is that it is "paid for," meaning it taps new revenue streams or ends other things that cost money so that the $550 billion in new spending in the plan doesn't add to the federal deficit.
Even though Trump's rebate rule has already been delayed and is likely to be killed, it is, at this moment, on the books. Since the infrastructure bill would delay the rule and its costs until 2026, the savings get counted as offsetting the new spending. Confused yet?
Delaying the rule, instead of killing it outright, means there's still another $130 billion on the books that can be used to offset other spending — almost certainly likely to help fund the even bigger budget reconciliation measure that Senate Democrats intend to pursue as soon as the Senate passes the bipartisan infrastructure bill.
Sen. Bill Cassidy (R-La.), who liked Trump's rule and also supports the bipartisan infrastructure bill, explained the reasoning to reporters shortly before the infrastructure legislation was released.
"The Medicare rebate rule — you know, I actually agree with the policy, but it was a $182 billion cost to the Treasury," Cassidy said, citing a slightly different figure for the savings. "And so, it's been signaled that it was going to be used for something. … Just speaking practically, if something's going to score that high, and here with a party, Democrats, that don't like it, it's going to go away, right? So that was just a good take."
The move is essentially painless in congressional budget terms, and PBMs are thrilled. They argue they do not actually profit from the rebates they negotiate in Part D and pass all the rebate cash along to Medicare and plan sponsors already.
They say their ability to negotiate those rebates is part of what makes them valuable, and the rule interferes. "That's sort of the bread and butter of the work that our companies do, and undermining the ability to provide that value is obviously a real challenge," Pharmaceutical Care Management Association CEO JC Scott said in a call with KHN and PCMA spokesperson Charles Coté.
They favor not just delaying it but spiking it completely. "From our perspective, that is the action that's needed," said Coté. "To create certainty for Part D and for beneficiaries, it should just be fully repealed."
Repealing Trump's rebate rule is not painless for people who have high drug costs, though, because, as Johns Hopkins professor Anderson explained, the 10% or so of people who would get significant rebates at the pharmacy counter would be better off.
"It helps the people that have the large bills; it harms the most the people that don't have the large bills," Anderson said.
Benefiting from Trump's rule would be drugmakers, according to the CBO data and other sources. In a statement from the Pharmaceutical Research and Manufacturers of America, the industry's lobby group, spokesperson Debra DeShong cast ending the rule as a windfall for PBMs and a cynical raid on cash meant for sick, older Americans.
"Lawmakers are threatening to gut a rule that would provide patients meaningful relief," DeShong said. "This would be an unconscionable move that robs patients of the prescription drug savings they deserve to help fill potholes and fund other infrastructure projects."
Senate lawmakers were hoping to pass the infrastructure bill by Thursday, then move quickly on the reconciliation bill, both paid for in part with the ill-fated rebate rule. The legislation would then go to the House when it returns from its August recess.
America's COVID-19 vaccination rate is around 60% for ages 12 and up. That's not enough to reach so-called herd immunity, and in states like Missouri — where a number of counties have vaccination rates under 25% — hospitals are overwhelmed by serious outbreaks of the more contagious delta variant.
The vaccine resisters offer all kinds of reasons for refusing the free shots and for ignoring efforts to nudge them to get inoculated. Campaigns urging Americans to get vaccinated for their health, for their grandparents, for their neighbors, or to get free doughnuts or a free joint haven't done the trick. States have even held lotteries with a chance to win millions or a college scholarship.
And yet there are still huge numbers of unvaccinated people. Federal, state and municipal governments as well as private businesses continue to largely avoid mandates for their employees out of fears they will provoke a backlash.
So, how about an economic argument? Get a COVID shot to protect your wallet.
Getting hospitalized with COVID in the United States typically generates huge bills. Those submitted by COVID patients to the NPR-Kaiser Health News "Bill of the Month" project include a $17,000 bill for a brief hospital stay in Marietta, Georgia (reduced to about $4,000 for an uninsured patient under a "charity care" policy); a $104,000 bill for a 14-day hospitalization in Miami for an uninsured man; and a bill for possibly hundreds of thousands for a two-week hospital stay — some of it on a ventilator — for a foreign tourist in Hawaii whose travel health insurance contained a "pandemic exclusion."
Even though insurance companies negotiate lower prices and cover much of the cost of care, an over $1,000 out-of-pocket bill for a deductible — plus more for copays and possibly some out-of-network care — should be a pretty scary incentive.
In 2020, before COVID vaccines, most major private insurers waived patient payments — from coinsurance to deductibles — for COVID treatment. But many if not most have allowed that policy to lapse. Aetna, for example, ended that policy Feb. 28; UnitedHealthcare began rolling back its waivers late last year and ended them by the end of March.
More than 97% of hospitalized patients last month were unvaccinated. Though the vaccines will not necessarily prevent you from catching the coronavirus, they are highly effective at assuring you will have a milder case and are kept out of the hospital.
For this reason, there's logic behind insurers' waiver rollback: Why should patients be kept financially unharmed from what is now a preventable hospitalization, thanks to a vaccine that the government paid for and made available free of charge? It is now in many drugstores, it's popping up at highway rest stops and bus stops, and it can be delivered and administered at home in parts of the country.
A harsher society might impose tough penalties on people who refuse vaccinations and contract the virus. Recently, the National Football League decreed that teams will forfeit a game canceled because of a COVID outbreak among unvaccinated players — and neither team's players will be paid.
But insurers could try to do more, like penalizing the unvaccinated. And there is precedent. Already, some policies won't cover treatment necessitated by what insurance companies deem risky behavior, such as scuba diving and rock climbing.
The Affordable Care Act allows insurers to charge smokers up to 50% more than what nonsmokers pay for some health plans. Four-fifths of states follow that protocol, though most employer-based plans do not do so. In 49 states, people caught driving without auto insurance face fines, confiscation of their car, loss of their license and even jail. And reckless drivers pay more for insurance.
The logic behind the policies is that the offenders' behavior can hurt others and costs society a lot of money. If a person decides not to get vaccinated and contracts a bad case of COVID, they are not only exposing others in their workplace or neighborhoods; the tens or hundreds of thousands spent on their care could mean higher premiums for others as well in their insurance plans next year. What's more, outbreaks in low-vaccination regions could help breed more vaccine-resistant variants that affect everyone.
Yes, we often cover people whose habits may have contributed to their illness — insurance regularly pays for drug and alcohol rehab and cancer treatment for smokers.
That's one reason, perhaps, that insurers too have so far favored carrots, not sticks, to get people vaccinated. Some private insurers are offering people who get vaccinated a credit toward their medical premiums, or gift cards and sweepstakes prizes, according to America's Health Insurance Plans, an industry organization.
Tough love might be easier if the Food and Drug Administration gives vaccines full approval, rather than the current emergency use authorization. Even so, taxpayer-financed plans like Medicaid and Medicare must treat everyone the same and would encounter a lengthy process to secure federal waivers to experiment with incentives, according to Larry Levitt, executive vice president of KFF, a nonprofit focusing on health issues. (Kaiser Health News, where Rosenthal is editor-in-chief, is one program under KFF.) These programs cannot charge different rates to different patients in a state.
KFF polling shows such incentives are of limited value, anyway. Many holdouts say they will be vaccinated only if required to do so by their employers.
But what if the financial cost of not getting vaccinated were just too high? If patients thought about the price they might need to pay for their own care, maybe they would reconsider remaining unprotected.
Madison Cano knew she wanted to breastfeed her son, Theo. But breastfeeding was painful for her. The skin on her breasts was chafed and blistered last July when she returned home from the hospital. And Theo sometimes screamed during feedings.
Cano, 30, realized she needed help to get the short- and long-term health benefits of breastfeeding for moms and babies. New studies also have shown that covid-vaccinated mothers pass protective antibodies on to their newborns. However, Cano lives in Montrose in western Colorado, 60 miles away from her lactation counselor, Ali Reynolds, in Grand Junction — and it was during the thick of the pandemic.
She messaged Reynolds on Facebook and took photos and recorded videos of herself breastfeeding so Reynolds could offer advice and encouragement from afar. It worked. She no longer had pain. Cano is still breastfeeding Theo, who just turned 1.
“I don’t think I would have understood what was happening and been able to work through it without that resource,” said Cano.
Support for breastfeeding was upended last year, when it no longer seemed safe to take a baby class at the hospital or invite a nurse into one’s home. Hospitals, lactation counselors and support groups turned to virtual platforms like Zoom or phone calls. That made lactation support accessible to struggling families during the pandemic, said Danielle Harmon, executive director of the United States Lactation Consultant Association.
Today, although lactation specialists have more options to safely meet in person with families after their covid-19 vaccinations, many are choosing to continue virtual classes, keeping alive the online communities they created and relying on the technology that worked for many families. Virtual options especially help those in remote areas or those with limited transportation access, breastfeeding experts say.
Right before the pandemic, for example, Sandrine Druon typically had one or two moms attend in-person meetings she held for La Leche League of Longmont at the First Evangelical Lutheran Church or at a Ziggi’s Coffee shop. But because they could no longer meet in person, last June she launched two monthly virtual meetings. Now, an online meeting will typically include nine or 10 moms. She started an online Spanish-speaking meeting in May and parents joined from their homes in several states and even from other countries. She hopes eventually to have a mix of online and in-person meetings.
The virtual switch hasn’t worked for everyone. Harmon said the logistics of video support remain difficult, along with privacy concerns on platforms that could be hacked. Other lactation experts noted Black and Hispanic mothers are sometimes still left behind. So lactation specialists are trying to learn from the pandemic on what worked — and what didn’t — to reach all kinds of new parents.
Before the pandemic, 84% of U.S. mothers breastfed at least initially, according to 2019 data from the Centers for Disease Control and Prevention, while Colorado had a 93% rate.
The pandemic hasn’t seemed to change the picture, said Stacy Miller, Colorado’s breastfeeding coordinator for the Special Supplemental Nutrition Program for Women, Infants and Children, shorthanded as WIC. Citing state birth certificate data, Miller said preliminary breastfeeding rates among families discharged from Colorado hospitals remained similar in the first quarter of 2021 to rates from 2020 or 2019.
Throughout the pandemic, lactation specialists have tried to offer convenient options for parents. St. Joseph Hospital in Denver launched virtual breastfeeding support groups that still occur today, in addition to breastfeeding help during families’ hospital stays, said Katie Halverstadt, the hospital’s clinical nurse manager of lactation and family education.
Last year in North Carolina, experts adapted an in-person prenatal breastfeeding program to an interactive video platform in English and Spanish. A separate effort on New York’s Long Island successfully converted in-person breastfeeding support to phone and video calls in 2020.
To help support parents in Grand Junction, Colorado, Reynolds expanded her private practice, Valley Lactation, by offering virtual appointments while continuing to see some clients in their homes. That hybrid model continues today, although Reynolds said the demand for virtual or phone appointments has decreased lately as the country reopens.
Paying out-of-pocket for appointments is a hurdle her clients face, said Reynolds, but she encourages them to submit claims for telehealth or in-person visits to their health insurance companies for reimbursement. Early in the pandemic, telehealth rules were relaxed to encourage more telephone and virtual appointments — many of which have been covered by insurance.
But insurance coverage for lactation support will likely continue to be an issue independent of whether pandemic telehealth rules expire, USLCA’s Harmon said. While the Affordable Care Act mandates that insurance companies cover lactation support and supplies, such as breast pumps, Harmon said reimbursement is often spotty. Mirroring Medicaid, insurance providers often cover services only from licensed providers, she said, but just four states — Georgia, New Mexico, Oregon and Rhode Island — license lactation consultants.
Experts such as Jennifer Schindler-Ruwisch, an assistant professor at Fairfield University in Connecticut, found the pandemic may have exacerbated breastfeeding barriers for those without access to online technology or translation services, among other things. She published one of the first studies in the U.S. to examine covid’s effect on lactation services by collecting experiences from lactation support providers in Connecticut, including many working in WIC programs. For income-eligible WIC families, all breastfeeding classes, peer groups and one-on-one consultations are free.
Birdie Johnson, a doula who provides breastfeeding and other postpartum support to Black families as part of Sacred Seeds Black Doula Collective of Colorado, said virtual support groups during the pandemic also did not meet her clients’ needs for connection and interaction. Social media built communities online, particularly by normalizing breastfeeding struggles among Black parents, she said, but obstacles remained.
“Covid brought our community together and at the same time destroyed it,” Johnson said.
Black parents in the U.S. already had lower rates of breastfeeding than Asian or white parents, according to 2017 CDC data, and both Black and Hispanic parents have had lower rates of exclusively breastfeeding their babies at 6 months, which is what the American Academy of Pediatrics recommends. Socioeconomics and lack of workplace support have been found to contribute to the gap. Research also has found Black mothers are more likely than white moms to be introduced to infant formula at hospitals.
A scarcity of Black health care providers in lactation, women’s health and pediatrics is a continuing concern, Johnson said. In Colorado last year, the Colorado Breastfeeding Coalition, the Center for African American Health, Elephant Circle and Families Forward Resource Center held three training sessions for people of color to become lactation specialists, said Halverstadt, who chairs the coalition.
Jefferson County, which encompasses much of Denver’s western suburbs, is now training at least a dozen Spanish-speaking community members for lactation certification. In addition to classes, the trainees log clinical hours in breastfeeding support, sometimes during virtual meetings of a Spanish-speaking support group called Cuenta Conmigo Lactancia.
“You are more confident and more at ease with someone who knows your language, your culture and who is part of the community,” said Brenda Rodriguez, a dietitian and certified lactation consultant for Jefferson County Public Health, which reaches roughly 400 breastfeeding families each month through its WIC programs.
Angelica Pereda, a maternal and child health registered nurse, is part of that training program. Pereda, who is Hispanic and bilingual, gave birth to son Ahmias in April 2020 and struggled with breastfeeding because he could not latch on to her breasts. A lactation consultant could not come into her home during the pandemic, and she was skeptical of virtual consultations because of privacy concerns. So she pumped her breast milk and bottle-fed it to her son.
Her experience gave her newfound empathy for families, and she wants to help other Spanish-speaking parents find solutions — whether in person or virtually.
“There is just not enough breastfeeding support in general, but especially when that support is in a different language,” said Pereda.